Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.27 USD

74.27
1,233,593

+0.49 (0.66%)

Updated Aug 19, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Stock Reports for Toyota, CVS Health & 3M

Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor (TM), CVS Health (CVS) and 3M (MMM).

Gilead (GILD) Announces Positive Long-Term Data on Yescarta

Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.

Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV

Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.

Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

Intercept's (ICPT) NDA for NASH Drug Gets Priority Review

Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.

AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL

The FDA approves AstraZeneca's (AZN) Calquence to treat CLL patients, based on positive data from two phase III studies.

Sweta Killa headshot

Biotech ETF (BBH) Hits New 52-Week High

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv

The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv

Mark Vickery headshot

Top Research Reports for Toyota, Netflix & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor (TM), Netflix (NFLX) and AbbVie (ABBV).

Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y

Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on Impressive Q3 Earnings Results

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.

The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More

Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.

Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.

Callaway Golf, FedEx, Amazon, Intel and Gilead highlighted as Zacks Bull and Bear of the Day

Callaway Golf, FedEx, Amazon, Intel and Gilead highlighted as Zacks Bull and Bear of the Day

Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat

Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.

Mark Vickery headshot

Q3 Earnings Frenzy: Amazon (AMZN), Intel (INTC) & More

Amazon missed earnings estimates, while Intel beat again and Gilead was in-line with expectations.

Gilead Sciences (GILD) Misses Q3 Earnings Estimates

Gilead (GILD) delivered earnings and revenue surprises of -0.57% and 0.10%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Why Gilead (GILD) Might Surprise This Earnings Season

Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences

The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences

Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings?

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2019 results.

Mark Vickery headshot

Top Stock Reports for U.S. Bancorp, Bristol-Myers Squibb & Morgan Stanley

Today's Research Daily features new research reports on 16 major stocks, including U.S. Bancorp (USB), Bristol-Myers Squibb (BMY) and Morgan Stanley (MS).

Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?

During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.

Sweta Killa headshot

What's in Store for Healthcare ETFs in Q3 Earnings?

With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.